Logo

RadioMedix and Orano Med’s AlphaMedix Receives the US FDA’s Breakthrough Therapy Designation for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Share this
Radiomedix

RadioMedix and Orano Med’s AlphaMedix Receives the US FDA’s Breakthrough Therapy Designation for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Shots:

  • The US FDA has granted BTD to RadioMedix and Orano Med’s AlphaMedix (212Pb-DOTAMTATE) to treat adults with unresectable/metastatic, progressive somatostatin receptor-expressing GEP-NETs who are not treated with peptide receptor radionuclide therapy (PRRT)
  • The designation was supported by the data from P-I, demonstrating an ORR of 62.5%, & an ongoing P-II studies investigating the safety and efficacy of AlphaMedix. The target response rate has been attained in the P-II while top-line results are anticipated in mid-2024
  • AlphaMedix comprises of SSTR-targeting peptide complex radiolabeled with 212Pb which produces alpha particles for destroying cancer cells while reducing toxicity to nearby healthy tissues

Ref: Oranomed | Image: Radiomedix

Related News:- CG Oncology’s Cretostimogene Grenadenorepvec Receives FTD and BTD from the US FDA for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions